Inven2
VC Fund
Oslo, Norway
Inven2 is a VC fund in Oslo focused on Biotechnology and Pharmaceutical. Inven2 specializes in the commercialization of research and to make outstanding research into the industry of the future.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Inven2 invests in
Stages Inven2 invests in
Countries Inven2 invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 2 (100%)
- Pharmaceutical 2 (100%)
- Medical 1 (50%)
- Health Care 1 (50%)
- Therapeutics 1 (50%)
Stage
- Series A 1 (50%)
- Post-IPO Equity 1 (50%)
Country
- Norway 1 (50%)
- Sweden 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
| CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Zelluna Immunotherapy AS is a privately owned Norwegian biopharmaceutical company founded in 2016 focused on the development of TCR based immunotherapies.Our goal is to revolutionize cancer therapy by developing TCR based therapies with the potential to treat a wide range of cancer types and patients.Zelluna’s core asset is a wide range of TCRsisolated from patients who exhibited long-term survival following inclusion in peptide based cancer vaccine trials initiated by Prof Gustav Gaudernack and conducted by investigators at the Norwegian Radium Hospital/Oslo University Hospital. Currently the company has several TCRs in different stages of development.We are a member of Oslo Cancer Cluster (Norwegian Centre of Expertise), a member organization for Norwegian and International stakeholders within cancer research and development. Oslo Cancer Cluster has members from the biotechnology industry, the government, patient organizations, research institutions and hospitals.Zelluna is located at the Oslo Cancer Cluster Innovation Park, next to the Norwegian Radium Hospital/Oslo University Hospital, the Department for Cellular Therapy and one of Europe’s largest academic certified GMP facilities for cellular products. | $925.7K / Post-IPO Equity / Aug 04, 2026 | ||
| Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. | $24.7M / Series A / Mar 26, 2025 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Inven2 invest in?
Inven2 invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series A and Post-IPO Equity stage. Most of the 2 investments tracked by Shizune back companies in Norway. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Inven2?
Public channels for Inven2 include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Inven2?
The team at Inven2 includes Ole Kristian Hjelstuen (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
